Frequently Asked Questions

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Frequently Asked Questions"

Transcription

1 Frequently Asked Questions Testing for Gonorrhea Q1: What test should be completed for accurately diagnosing gonorrhea? A1: Testing is done with either a culture or a NAAT (nucleic acid amplification test). Regardless of symptoms, it is important to test all sites that may have been exposed, including rectum or pharynx. Over the past several years, gonorrhea has become harder to treat because drug-resistant strains of gonorrhea are increasing in many parts of the world and Canada. In order to monitor drug-resistant gonorrhea in Saskatchewan and to better guide treatment, testing should be conducted as outlined in the algorithm in Question #4. Successful culturing of N. gonorrhea is dependent on several factors associated with specimen collection, transportation and storage. For example: collection method, transport (loss of viability due to transport or storage temperature or duration of transport,) overgrowth of N. gonorrhea by competing organisms in the sample collected, and dilution of the organism in collection medium. The result of any of these factors may lead false negative culture results (Association of Public Health Laboratories, 2014). NAAT is an appropriate alternative to cultures when the above criteria cannot be met. Q2: What are the signs and symptoms consistent with gonorrhea infection? A2: Individuals with gonorrhea may have mucopurulent discharge of the urethra or cervix. Symptoms of rectal infection may include discharge, anal itching, soreness, bleeding or painful bowel movements. Individuals with a history of oral sex may have pharyngeal infection, however these infections are usually asymptomatic. Q3: What are the risk factors for gonorrhea? A3: Individuals are at increased risk for gonorrhea if one or more of the following apply: Sexual contact with a person with a confirmed or suspected gonococcal infection; Unprotected sex with a resident of an area with high gonorrhea burden or high risk of antimicrobial resistance; History of previous gonococcal infection; History of other STIs, including HIV; Sex workers and their sexual partners; Sexually active youth < 25 years of age; Street-involved youth and other homeless populations; Men who have unprotected sex with men; and Sex with multiple partners. September 2014 Page 1

2 Q4: What testing should be completed for patients? A4: The following algorithm outlines the most appropriate testing based on client risk factors and clinical presentation. Obtain cultures (cervix or urethra) prior to NAAT specimens from symptomatic individuals with risk factors. Screen asymptomatic individuals for infection by NAAT on genital tract specimens (urine or cervix). Obtain cultures and NAATs from rectal or pharyngeal sites from individuals who have unprotected sexual exposure at these sites. NOTE: Chlamydia should be tested at the same time as gonorrhea in all cases. Gonorrhea Screening Recommendations Does the Patient Have Risk Factors (see Q#3)? If yes, proceed in the chart: Symptoms No Symptoms Is there Rectal or Pharyngeal Exposures*? Males Females Males and Females Culture AND Endocervial culture Urethral Culture (1st) and Urine NAAT and Endocrevical, vaginal or urine NAAT Urine NAAT (and cervical swab if doing pelvic exam) NAAT * For all symptomatic individuals and asymptomatic men who have sex with men and women with a history of performing oral sex. Source: Public Health Agency of Canada (2013) Adapted from Public Health Ontario (2013) Q5: What are the specimen collection and transport requirements? A5: Refer to the Saskatchewan Disease Control Laboratory (SDCL) Compendium of Tests (http://www.health.gov.sk.ca/compendium) Bacteriology: Gonococcal Culture for details and contact your regional lab to obtain appropriate materials that are not supplied by SDCL. September 2014 Page 2

3 Treatment Recommendations Q6: What is the recommended treatment for uncomplicated gonorrhea (ano-genital or pharyngeal gonorrhea) in Saskatchewan? A6: Until further notice, first-line treatment for persons above nine years of age (including pregnant women and nursing mothers) with confirmed or suspected uncomplicated urogenital gonorrhea (cervix, vagina, pharynx or rectum) and their sex partners is Ceftriaxone 250 mg intramuscularly plus azithromycin 1g orally. Q7: Why are two antimicrobials recommended to treat gonorrhea? A7: Treatment of gonorrhea with two antimicrobials is recommended nationally to improve the efficacy of treatment and delay the emergence and spread of resistance in N. gonorrhoeae. Cephalosporin-azithromycin combination therapy has also been found to be more effective in treating pharyngeal infections, which are usually asymptomatic. Q8: Is azithromycin being used to treat chlamydia or gonorrhea? A8: Both. Individuals with gonorrhea are commonly co-infected with chlamydia. Azithromycin treats chlamydia and also acts synergistically with cephalosporin to treat gonorrhea. Q9: When should treatment be provided? A9: In general, do not provide treatment for gonorrhea until there is laboratory evidence of gonorrhea infection. However, provide empiric treatment prior to receiving confirmatory lab results in the following circumstances: Patient presents with urethra/cervical mucopurulent discharge: If the partner is infected with gonorrhea, ceftriaxone and azithromycin should be provided; OR If follow-up is not assured, ceftriaxone and azithromycin should be provided; OR Provide azithromycin to treat chlamydia and if local prevalence of gonorrhea is high (contact your medical health officer if you require details of local epidemiology), consider treating with ceftriaxone. Patient presents without urethral/cervical mucopurulent discharge: If the individual is at high risk for infection and follow-up is not assured, provide ceftriaxone and azithromycin; OR If the sexual partner is infected with gonorrhea, provide ceftriaxone and azithromycin. Q10: What is the recommendation for second line treatment for gonorrhea? A10: Because cefixime is currently not available, second line options are Spectinomycin 2 g intramuscular plus Azithromycin 1 g orally OR Azithromycin 2 g orally (SEE BOX BELOW: Cautions regarding Azitthromycin). Note: Spectinomycin is only available through Health Canada s Special Access Programme using Form A September 2014 Page 3

4 Cautions regarding Azithromycin Azithromycin 2 g PO in a single dose should only be considered as an alternate treatment option if there is a history of severe allergy to cephalosporins. There are also significant gastrointestinal side effects associated with high dose azithromycin (Public Health Agency of Canada, 2013). Azithromycin is not recommended as monotherapy because of concern over the emergence of resistance. Instead, a 1 g dose of azithromycin is recommended as a component of dual therapy for gonorrhea, in conjunction with a cephalosporin (i.e., 250 mg of ceftriaxone) (CDC, 2011). An azithromycin-resistant variant of gonorrhea that developed in just 12 days was detected with genotyping highlighting the rapid emergence of clinical gonococcal resistance (Hill, 2012). Azithromycin can cause potentially life-threatening arrhythmias, especially in individuals taking a multi-day course of the medication. Individuals most at risk of this are those who have prolonged QT interval, other cardiac conditions (bradycardia, heart failure) or are elderly (Public Health Agency of Canada, 2013). Q11: What do I do if my patient has an allergy to penicillin? A11: Patients with a history of a severe reaction to penicillin, or any allergic reaction to the cephalosporins should be prescribed a non-cephalosporin based regimen for any suspected or confirmed gonorrhea infection and referred to a drug allergy clinic if available. Therapies to consider in this context include Spectinomycin 2 g intramuscular plus azithromycin 1g orally, or azithromycin 2 g orally (note cautions around using azithromycin as monotherapy noted above). Both of these treatments require a test of cure. Only a small number of patients that are told that they have a penicillin allergy will have any reaction if they take a cephalosporin. The estimated rates of severe reactions to the administration of a cephalosporin to an individual with a history of a penicillin allergy are between and 0.1%. Q12: What do I do if my patient has an allergy to azithromycin? A12: Allergies to azithromycin are extremely rare. In the instance of allergy to azithromycin, doxycycline 100 mg PO BID x 7 days is recommended in addition to ceftriaxone 250 mg IM. This treatment requires a test of cure. Doxycycline is contraindicated in pregnant and breastfeeding women. Q13: What do I do if my patient did not receive first line therapy (ceftriaxone and azithromycin)? A13: A test of cure is recommended to ensure the infection has been cleared. If infection is cleared, no additional treatment is necessary. If gonorrhea infection is still present, treatment with both ceftriaxone and azithromycin is recommended. Chlamydia testing should also be ruled out as a possible co-infection for all individuals who have been identified with gonorrhea. If chlamydia infection is identified, treatment is suggested as per the Saskatchewan Communicable Disease Control Manual September 2014 Page 4

5 Q14: What is a Test of Cure? A14: A Test of Cure is laboratory tests conducted at a defined timeframe following the completion of treatment to ensure the infection has resolved. Q15: How do I do a Test of Cure? A15: For Test of Cure, regardless of presence or absence of symptoms, the preferred testing method is culture. Test of Cure using culture should be performed four to five days after completion of therapy. If culture is not locally available, NAAT testing is a second-line option, but should be performed four weeks post-treatment at the earliest. Q16: When should I do a Test of Cure? A16: Test of Cure by culture should be completed whenever ceftriaxone AND azithromycin has not been provided. In addition to the above, Test of Cure by culture (4-5 days post treatment) if the client has: pharyngeal infection; persistent post-treatment symptoms; and been linked to drug resistance or treatment failure. Test of Cure by culture (4-5 days post treatment) or PCR (urine NAAT) (4 weeks post treatment) if the client: Is 16 years of age or under; Is pregnant; Has concomitant infections; Is concerned about re-infection; Is a man who has sex with men; Is a prepubertal child; Is diagnosed with pelvic inflammatory disease (PID); and Experienced treatment failure previously. Q17: How long do cases have to abstain from sex following this new treatment? A17: Advise patients and contacts to abstain from unprotected intercourse until 7 days after completion of treatment. Q18: What information should be provided to my patients about treatment? A18: Patient information sheets on gonorrhea and the medications are available. Inform your patients about contraindications, side effects, drug interactions and the length of time that they should abstain from unprotected intercourse (i.e. for seven days following completion of treatment). Q19: When should treated cases of gonorrhea be re-screened for STI? A19: Individuals diagnosed with gonorrhea are at high risk of reinfection. Rescreen patients who are diagnosed with gonorrhea six months after initial diagnosis, or when they next seek medical care within the next 12 months (Public Health Agency of Canada, 2013). September 2014 Page 5

6 Management of Contacts Q20: Who is a contact? A20: All partners who have had sexual contact with the case (including oral, anal and vaginal) within 60 days prior to symptom onset or when the specimen was collected if the case was asymptomatic. If your patient indicates having no partners in the past 60 days, the most recent partner should be notified (Public Health Agency of Canada, 2013). Q21: How do I manage a contact? A21: All contacts should be assessed, tested, treated empirically and counseled. Q22: What is required as part of an assessment? A22: In addition to the physical assessment, a risk assessment should be completed to determine if the contact has more risks than the known exposure. See Attachment Risk Assessment Questionnaire in the Saskatchewan Communicable Disease Control Manual: Q23: What testing is required for contacts? A23: Testing (culture versus NAAT) should be conducted based on symptoms. See Questions #1 and #4 for Gonorrhea Testing Recommendations (Symptomatic or Asymptomatic Patients). In addition to completing gonorrhea tests, test contacts for chlamydia, syphilis and HIV due to the increased risk of co-infection with other STIs. Additional tests should be completed based on the risk assessment. Q24: How do I treat a contact? A24: Give empiric treatment with ceftriaxone 250 mg intramuscularly plus azithromycin 1 g orally as soon as possible to all sexual contacts of cases regardless of clinical findings and without waiting for test results (Public Health Agency of Canada, 2013). Empiric treatment is recommended to reduce the risk of further transmission and the potential of re-infecting their treated partner. Q25: What counseling should be provided to contacts? A25: Patient information sheets on gonorrhea and the medications are available. Provide contacts information about contraindications, side effects, drug interactions and the length of time that they should abstain from unprotected intercourse (i.e. for 7 days following completion of treatment). Recommend STI testing every six months for at-risk individuals. September 2014 Page 6

7 Administration and Access to STI medications Q26: Who is eligible to access publicly-funded STI medications in Saskatchewan? A26: In Saskatchewan, STI medications are publicly funded to facilitate effective treatment in a timely manner for individuals who have laboratory confirmed STI or who are eligible for empiric treatment (See Question #9). To order publicly-funded STI medications, please contact your local public health unit. To find the public health unit nearest you, please visit: Publicly funded medications are available for treatment of notifiable sexually transmitted infections. As such, for each dose of medication provided, an accompanying notification form must be completed indicating if the disease that is suspected or confirmed. See attached. Q27: Should health care practitioners keep a limited stock of STI medications in the clinic? A27: Yes. To facilitate timely treatment of patients and reduced transmission of STIs, it is recommended that health care practitioners keep a limited stock of STI medications in their clinic to provide treatment of clients with a STI (i.e., laboratory confirmed case or those requiring empiric treatment) at their clinic. Consult with your local public health unit Q28: How should ceftriaxone for IM injection be stored? A28: Ceftriaxone for injection sterile powder should be stored at C (room temperature) and protected from light. Solutions should be reconstituted immediately before use. If storage is required (after reconstitution), these solutions may be stored under refrigeration and should be used within 48 hours. See product monograph: all%20strengths_rev2.pdf: Q29: What diluents should be used for reconstitution of ceftriaxone for IM injection? A29: The preferred diluent for reconstituting ceftriaxone is lidocaine (1%) and is publicly funded when used for this purpose. The following solutions may also be used for reconstitution for intramuscular injection in the event of a contraindication to lidocaine, but these solutions are not publicly funded. Sterile Water for Injection 0.9% Sodium Chloride Injection 5% Dextrose Injection Bacteriostatic Water for Injection For detailed information about the agent used as a diluent for the specific product received from your local health unit please refer to the product monographs at _all%20strengths_rev2.pdf and September 2014 Page 7

8 Q30: Should ceftriaxone 250 mg IM be administered with safety engineered needles? A30: As per Section 474.1(3) of the Saskatchewan Occupational Health and Safety regulations 1, the use of safety engineered needles are required by workers or self-employed persons. Q31: How do I prepare the injection? A31: Refer to the product monographs for ceftriaxone for full details and other diluent options: all%20strengths_rev2.pdf. Q32: How should ceftriaxone be administered? A32: The medication should be administered IM into the intragluteal region. Aspirate following needle placement to avoid injecting intravenously. See below for description and images of appropriate land marking 2. Dorsogluteal site Draw an imaginary line from the posterior superior iliac spine to the greater trochanter. Insert the needle at a 90-degree angle above and outside the drawn line. You can administer a Z-track injection through this site. After drawing up the drug, change the needle, displace the skin lateral to the injection site, withdraw the needle, and then release the skin. Ventrogluteal site With the palm of your hand, locate the greater trochanter of the femur. Spread your index and middle fingers posteriorly from the anterior superior iliac spine to the furthest area possible. This is the correct injection site. Remove your fingers and insert the needle at a 90-degree angle Source: September 2014 Page 8

9 Follow-Up of Individuals Q33: What is the definition of Gonorrhea Treatment Failure? A33: Gonorrhea Treatment Failures are defined as treated individuals with confirmed gonorrhea and a positive test of cure (NAAT or culture) in the absence of risk of reinfection (i.e., patient denies potential sexual re-exposure) (Public Health Agency of Canada, 2014). False positive results may occur if a culture was taken less than 4 days after treatment or the NAAT was taken less than 4 weeks after treatment. Q34: What do I do if I am concerned that my patient has had treatment failure? A34: If first-line treatment was not used initially, use the first-line treatment, if no contraindications. Perform a test of cure using culture four to five days post re-treatment. Report any suspected or confirmed gonorrhea treatment failures to your local public health unit. Once notified of a suspected or confirmed case of gonorrhea treatment failure, the public health unit will work with the responsible health care practitioner to provide notification to Saskatchewan Ministry of Health and to discuss any further public health action that may be required. Q35: Why do I need to disclose treatment failures to my local Medical Health Officer? A35: Disclosure is required in order to monitor resistance patterns of multi-drug resistant N. gonorrhoeae, to ensure individuals are being treated effectively for gonorrhea, and to limit ongoing transmission. In order to do this, health care practitioners, local public health units and the Saskatchewan Ministry of Health must work together to make sure each is aware of treatment failures. Resources Q36: Where can I go to get more information? A36: There are several resources to turn to for more information regarding multi-drug resistant gonorrhea, and the assessment and management of gonorrhea and sexually transmitted infections in general. Your local public health office or medical health officer can answer questions you may have. You can also access the Saskatchewan Communicable Disease Control Manual online at Also see The Canadian Guidelines on Sexually Transmitted Infections (Public Health Agency of Canada): September 2014 Page 9

10 References Guidelines for Testing and Treatment of Gonorrhea in Saskatchewan, 2014 Association of Public Health Laboratories (2014) Specimens-for-Neisseria-gonorrhoeae-Culture.pdf British Columbia Centers for Disease Control - Public Health Agency of Canada - and Public Health Ontario (2013) - Saskatchewan Communicable Disease Control Manual - US Centers for Disease Prevention and Control - Hill (2012) Gonorrhea Develops Rapid Resistance to Azithromycin. Medscape. Mar 15, Centers for Disease Control and Prevention (2011) Neisseria gonorrhoeae with Reduced Susceptibility to Azithromycin, Morbidity and Mortality Weekly Report. 2011;60(18): September 2014 Page 10

Frequently Asked Questions

Frequently Asked Questions Guidelines for Testing and Treatment of Gonorrhea in Ontario, 2013 Frequently Asked Questions Table of Contents Background... 1 Treatment Recommendations... 2 Treatment of Contacts... 4 Administration

More information

THIS IS AN OFFICIAL NH DHHS HEALTH ALERT

THIS IS AN OFFICIAL NH DHHS HEALTH ALERT THIS IS AN OFFICIAL NH DHHS HEALTH ALERT Distributed by the NH Health Alert Network Health.Alert@nh.gov August 13, 2015 1400 EDT (2:00 PM EDT) NH-HAN 20150813 Updated Centers for Disease Control (CDC)

More information

Sexually Transmitted Infections Chlamydia and Gonorrhea Infection Control Education Sessions Bug of the Month

Sexually Transmitted Infections Chlamydia and Gonorrhea Infection Control Education Sessions Bug of the Month Sexually Transmitted Infections Chlamydia and Gonorrhea Infection Control Education Sessions Bug of the Month Dr. Shauna Hudson, Medical Health Officer Lindsay Bowman, Communicable Disease/Immunization

More information

GONORRHOEA. Use of lidocaine as a diluent when using ceftriaxone (see Appendix 1)

GONORRHOEA. Use of lidocaine as a diluent when using ceftriaxone (see Appendix 1) Key practice notes: 1 st line therapy GONORRHOEA Decreasing sensitivity of gonorrhoea to cephalosporins is now a real threat: CEFTRIAXONE 500mg IM stat first-line for all gonococcal infections AZITHROMYCIN

More information

STD Section Services for Providers and Gonorrhea Update

STD Section Services for Providers and Gonorrhea Update STD Section Services for Providers and Gonorrhea Update Susan Philip, MD MPH Director, STD Prevention and Control Services San Francisco Department of Public Health Assistant Clinical Professor of Medicine

More information

TREATMENT OF STI CONTACTS

TREATMENT OF STI CONTACTS This decision support tool is effective as of October 2014. For more information or to provide feedback on this or any other decision support tool, email certifiedpractice@crnbc.ca TREATMENT OF STI CONTACTS

More information

CDC 2015 STD Treatment Guidelines: Update for IHS Providers Sharon Adler M.D., M.P.H.

CDC 2015 STD Treatment Guidelines: Update for IHS Providers Sharon Adler M.D., M.P.H. CDC 2015 STD Treatment Guidelines: Update for IHS Providers Sharon Adler M.D., M.P.H. Clinical Faculty, CA Prevention Training Center Disclosure Information Sharon Adler MD, MPH I have no financial relationships

More information

GONORRHEA (REPORTABLE)

GONORRHEA (REPORTABLE) This decision support tool is effective as of February 2014. For more information or to provide feedback on this or any other decision support tool, email certifiedpractice@crnbc.ca GONORRHEA (REPORTABLE)

More information

Expedited Partner Therapy (EPT) for Sexually Transmitted Diseases Protocol for Health Care Providers in Oregon

Expedited Partner Therapy (EPT) for Sexually Transmitted Diseases Protocol for Health Care Providers in Oregon Expedited Partner Therapy (EPT) for Sexually Transmitted Diseases Protocol for Health Care Providers in Oregon Oregon Health Authority Center for Public Health Practice HIV/STD/TB Section Principles of

More information

Gonorrhea FACTSHEET. Summary. What is gonorrhea?

Gonorrhea FACTSHEET. Summary. What is gonorrhea? FACTSHEET Gonorrhea Summary Gonorrhea is a sexually transmitted infection caused by a bacterium. It can be transmitted through sexual contact. All people who are sexually active may be at risk for gonorrhea.

More information

signs suggesting chlamydia:

signs suggesting chlamydia: Chlamydia - uncomplicated genital - Management View full scenario When should I suspect and test for chlamydia? Women: o Test for chlamydia if they are sexually active with symptoms and signs suggesting

More information

California Guidelines for STD Screening and Treatment in Pregnancy

California Guidelines for STD Screening and Treatment in Pregnancy California Guidelines for STD Screening and Treatment in Pregnancy These guidelines were developed by the California Department of Public Health (CDPH) Sexually Transmitted Diseases (STD) Control Branch

More information

Developed by: California Department of Public Health (CDPH) Sexually Transmitted Diseases (STD) Control Branch. In collaboration with:

Developed by: California Department of Public Health (CDPH) Sexually Transmitted Diseases (STD) Control Branch. In collaboration with: Best Practices for the Prevention and Early Detection of Repeat Chlamydial and Gonococcal Infections: Effective Partner Treatment and Patient Retesting Strategies for Implementation in California Health

More information

California Gonorrhea Treatment Guidelines

California Gonorrhea Treatment Guidelines Califnia Gonrhea Treatment Guidelines These guidelines were developed by the Califnia Department of Public Health (CDPH) Sexually Transmitted Diseases (STD) Control Branch in conjunction with the Califnia

More information

The Minnesota Chlamydia Strategy: Action Plan to Reduce and Prevent Chlamydia in Minnesota Minnesota Chlamydia Partnership, April 2011

The Minnesota Chlamydia Strategy: Action Plan to Reduce and Prevent Chlamydia in Minnesota Minnesota Chlamydia Partnership, April 2011 The Minnesota Chlamydia Strategy: Action Plan to Reduce and Prevent Chlamydia in Minnesota Minnesota Chlamydia Partnership, April 2011 Section 5: Screening, Treating and Reporting Chlamydia While the information

More information

STI case management. Francis Ndowa - GFMER Theodora Wi - WHO

STI case management. Francis Ndowa - GFMER Theodora Wi - WHO Training Course in Sexual and Reproductive Health Research 2014 Module: Principles and Practice of Sexually Transmitted Infections Prevention and Care STI case management Francis Ndowa - GFMER Theodora

More information

Changes in the 2010 STD Treatment Guidelines: What Adolescent Health Care Providers Should Know February 2011

Changes in the 2010 STD Treatment Guidelines: What Adolescent Health Care Providers Should Know February 2011 Changes in the 2010 STD Treatment Guidelines: What Adolescent Health Care Providers Should Know February 2011 Gale Burstein, MD, MPH, FAAP, FSAHM 1 Amanda Jacobs, MD, FAAP, 2 Dmitry Kissin, MD, MPH, 3

More information

Sexually Transmitted Diseases. Summary of CDC Treatment Guidelines

Sexually Transmitted Diseases. Summary of CDC Treatment Guidelines DC 2015 Sexually Transmitted Diseases Summary of CDC Treatment Guidelines These summary guidelines reflect the June 2015 update to the 2010 CDC Guidelines for Treatment of Sexually Transmitted Diseases.

More information

STD Treatment Chart Nancy Harris, N.P. Women s Health Coordinator August 2003 Disease Treatment Alternative treatment

STD Treatment Chart Nancy Harris, N.P. Women s Health Coordinator August 2003 Disease Treatment Alternative treatment STD Treatment Chart Nancy Harris, N.P. Women s Health Coordinator August 2003 Disease Treatment Alternative Pregnancy Chlamydia Chancroid Epdidymitis Gonorrhea: Uncomplicated (cx, urethra, and rectum):

More information

ALASKA NATIVE MEDICAL CENTER SEXUALLY TRANSMITTED DISEASE SCREENING AND TREATMENT GUIDELINES

ALASKA NATIVE MEDICAL CENTER SEXUALLY TRANSMITTED DISEASE SCREENING AND TREATMENT GUIDELINES ALASKA NATIVE MEDICAL CENTER SEXUALLY TRANSMITTED DISEASE SCREENING AND TREATMENT GUIDELINES A. Screening Page Chlamydia and Gonorrhea 1 HIV 1 Syphilis 1 Genital Herpes 2 Hepatitis A 2 Hepatitis B 2 Hepatitis

More information

Title: Antibiotic Guideline for Acute Pelvic Inflammatory Disease

Title: Antibiotic Guideline for Acute Pelvic Inflammatory Disease Title: Antibiotic Guideline for Acute Pelvic Inflammatory Disease Version 3 Date ratified December 2007 Review date December 2009 Ratified by NUH Antimicrobial Guidelines Committee Gynaecology Directorate

More information

Rhode Island Department of Health Division of Infectious Diseases and Epidemiology

Rhode Island Department of Health Division of Infectious Diseases and Epidemiology Rhode Island Department of Health Division of Infectious Diseases and Epidemiology STD (Sexually Transmitted Disease) PROGRAM Expedited Partner Therapy (EPT) for STDs Guidance for Medical Providers in

More information

How to Make Adolescent STD Screening Easy. Jill Grimes, MD

How to Make Adolescent STD Screening Easy. Jill Grimes, MD How to Make Adolescent STD Screening Easy Jill Grimes, MD Disclaimer This presentation reflects the opinions of Jill Grimes, MD, and is not intended to represent the opinions of the Seton family of hospitals.

More information

SCREENING FOR SEXUALLY TRANSMITTED INFECTIONS

SCREENING FOR SEXUALLY TRANSMITTED INFECTIONS SCREENING FOR SEXUALLY TRANSMITTED INFECTIONS Take history:- History of presenting problem Full sexual history (refer to guideline on sexual history taking) Relevant past medical history, including previous

More information

STANDARD PROTOCOL STD AND HIV SCREENING AND EPIDEMIOLOGIC STD TREATMENT

STANDARD PROTOCOL STD AND HIV SCREENING AND EPIDEMIOLOGIC STD TREATMENT STANDARD PROTOCOL STD AND HIV SCREENING AND EPIDEMIOLOGIC STD TREATMENT RELEASE DATE: REVIEW INTERVAL: YEARLY REVIEW DATE: SITE/SERVICE UNIT: IMPLEMENTATION DATE: REVIEWED BY: CONTACT: APPROVED BY: CONTENTS

More information

Sexually Transmitted Infections (STI) One Day Update

Sexually Transmitted Infections (STI) One Day Update Sexually Transmitted Infections (STI) One Day Update February 2015 Overview STI Guideline Changes National STI Services Results Reporting High Transmission Areas: Key Populations STI Guideline Changes

More information

Diseases that can be spread during sex

Diseases that can be spread during sex Diseases that can be spread during sex Did you know... over 65 million people in the United States have a chronic, incurable sexually transmitted disease (STD)? and that every year another 19 million persons

More information

Chlamydia THE FACTS. How do people get Chlamydia?

Chlamydia THE FACTS. How do people get Chlamydia? What is Chlamydia? Chlamydia is a common bacterial infection that is sexually transmitted and often causes no symptoms. If not treated, chlamydia can damage reproductive organs and make it difficult for

More information

Specimen collection and transport for Chlamydia trachomatis and Neisseria gonorrhoeae testing

Specimen collection and transport for Chlamydia trachomatis and Neisseria gonorrhoeae testing Specimen collection and transport for Chlamydia trachomatis and Neisseria gonorrhoeae testing Overview Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections are two of the most common sexually

More information

Treatment of sexually transmitted and other genital infections

Treatment of sexually transmitted and other genital infections www.bpac.org.nz keyword: sti Treatment of sexually transmitted and other genital infections Key reviewer: Dr Murray Reid, Sexual Health Physician, Auckland Sexual Health Service General points: If one

More information

SYPHILIS (REPORTABLE)

SYPHILIS (REPORTABLE) SYPHILIS (REPORTABLE) Please Note: On April 25, 2016, in collaboration with the Public Health Agency of Canada; the BCCDC issued interim Syphilis treatment guidelines effective immediately in response

More information

Gonorrhea. Pharyngeal gonorrhea. THE ENEMY: Neisseria Gonorhheae

Gonorrhea. Pharyngeal gonorrhea. THE ENEMY: Neisseria Gonorhheae Gonorrhea THE ENEMY: Neisseria Gonorhheae FUSSY gram positive diplococcus Pathogen ONLY of humans Increases transmission of HIV FIVEFOLD! About 700,000 cases yearly in the USA 1 in 5 males get GC with

More information

University Hospital for Infectious Diseases Dr. Fran Mihaljević, Zagreb, Croatia 2. Royal Free Hospital & JUSTRI London, UK

University Hospital for Infectious Diseases Dr. Fran Mihaljević, Zagreb, Croatia 2. Royal Free Hospital & JUSTRI London, UK Š. Zekan 1, M. Youle 2, O. Đaković Rode 1, S. Židovec Lepej 1, M. Kosanović 1, J. Begovac 1 1 University Hospital for Infectious Diseases Dr. Fran Mihaljević, Zagreb, Croatia 2 Royal Free Hospital & JUSTRI

More information

Slide 1: Chlamydia and Gonorrhea: What You and Your Clients Need to Know. Welcome to Chlamydia and Gonorrhea: What You and Your Clients Need to Know.

Slide 1: Chlamydia and Gonorrhea: What You and Your Clients Need to Know. Welcome to Chlamydia and Gonorrhea: What You and Your Clients Need to Know. Slide 1: Chlamydia and Gonorrhea: What You and Your Clients Need to Know Welcome to Chlamydia and Gonorrhea: What You and Your Clients Need to Know. This is a presentation for healthcare providers about

More information

CT/GC Morbidity 10/2/2015. Edward W. Hook III, M.D.

CT/GC Morbidity 10/2/2015. Edward W. Hook III, M.D. The 2015 CDC STD Treatment Guidelines for Gonorrhea and Chlamydial Management and The Importance of Time to Treatment Edward W. Hook III, M.D. University of Alabama at Birmingham Medicine, Microbiology

More information

Sexual Health and Sexually Transmitted Infections Prevention and Control Protocol, 2013 (Revised)

Sexual Health and Sexually Transmitted Infections Prevention and Control Protocol, 2013 (Revised) Sexual Health and Sexually Transmitted Infections Prevention and Control Protocol, 2013 (Revised) Preamble The Ontario Public Health Standards (OPHS) are published by the Minister of Health and Long- Term

More information

Sexually Transmitted Diseases

Sexually Transmitted Diseases Sexually Transmitted Diseases Chapter Fourteen 2013 McGraw-Hill Higher Education. All rights reserved. The Major Sexually Transmitted Diseases Also known as sexually transmitted infections The Major STDs

More information

Cover Your Lover: STD Facts

Cover Your Lover: STD Facts The Gable Health Center has partnered with the Pennsylvania State Department of Health to raise STD awareness in the Albright Community through the Cover Your Lover campaign. With approximately 12 million

More information

12/3/2015. M genitalium and urethritis and cervicitis. Consider M gent Rx in persistent /recurrent urethritis and in persistent cervicitis and PID

12/3/2015. M genitalium and urethritis and cervicitis. Consider M gent Rx in persistent /recurrent urethritis and in persistent cervicitis and PID M genitalium and urethritis and cervicitis Consider M gent Rx in persistent /recurrent urethritis and in persistent cervicitis and PID Azithromycin 1 gm more effective odoxy ineffective oaz Resistance

More information

Immunization Healthcare Branch. Human Papillomavirus Vaccination Program Questions and Answers. Prepared by

Immunization Healthcare Branch. Human Papillomavirus Vaccination Program Questions and Answers. Prepared by Immunization Healthcare Branch Human Papillomavirus Vaccination Program Questions and Answers Prepared by Immunization Healthcare Branch (IHB), Defense Health Agency Last Updated: 02 Jan 14 www.vaccines.mil

More information

Alberta Treatment Guidelines for Sexually Transmitted Infections (STI) in Adolescents and Adults 2012

Alberta Treatment Guidelines for Sexually Transmitted Infections (STI) in Adolescents and Adults 2012 Alberta Treatment Guidelines for Sexually Transmitted Infections (STI) in Adolescents and Adults 2012 General for STI Given the current rates of STI in Alberta, Some STI are under the Patients and contacts

More information

Sexually Transmitted Infections. Kelly Ruhstaller MD March 15, 2013

Sexually Transmitted Infections. Kelly Ruhstaller MD March 15, 2013 Sexually Transmitted Infections Kelly Ruhstaller MD March 15, 2013 Overview Review pathophysiology of common sexually transmitted infections including chlamydia, gonorrhea, trichimonas, herpes Discuss

More information

2. Characteristics of staff Qualifications required. Additional requirements. Continued education & training requirements

2. Characteristics of staff Qualifications required. Additional requirements. Continued education & training requirements Patient Group Direction The supply of Azithromycin 1g as a single dose by accredited Community Pharmacists to patients in receipt of a positive test result to Chlamydia trachomatis, and treatment of their

More information

Treat immediately if patient symptomatic and clinical suspicion of genital herpes.

Treat immediately if patient symptomatic and clinical suspicion of genital herpes. Genital Herpes MANAGEMENT SUMMARY TEST IF Patient presents with genital ulcers, sores or fissures. RECOMMENDED SAMPLE FOR GENITAL HERPES Female and male: Viral swab for herpes simplex virus testing. Base

More information

CHLAMYDIA CERVICITIS/URETHRITIS AND NON-GONOCOCCAL URETHRITIS (NGU)

CHLAMYDIA CERVICITIS/URETHRITIS AND NON-GONOCOCCAL URETHRITIS (NGU) CHLAMYDIA CERVICITIS/URETHRITIS AND NON-GONOCOCCAL URETHRITIS (NGU) DEFINITION SUBJECTIVE Infection of the cervix or urethra with Chlamydia trachomatis (CT). Chlamydia infection is a leading cause of acute

More information

Sexually Transmitted Infections (STIs) and the STI Clinic

Sexually Transmitted Infections (STIs) and the STI Clinic Patient & Family Guide 2016 Sexually Transmitted Infections (STIs) and the STI Clinic Where to go. What to know. STIs are more common than you might think! www.nshealth.ca Sexually Transmitted Infections

More information

WA Endemic Regions STI/HIV Control Supplement

WA Endemic Regions STI/HIV Control Supplement WA Endemic Regions STI/HIV Control Supplement MAY 2013 Contents INTRODUCTION... 2 HEALTH UNITS CONTACTS... 3 RATES OF CHLAMYDIA, GONORRHOEA AND SYPHILIS NOTIFICATIONS IN THE GOLDFIELDS, KIMBERLEY, MIDWEST

More information

Screening for Gonorrhea and Chlamydia: Systematic Review to Update the U.S. Preventive Services Task Force Recommendations

Screening for Gonorrhea and Chlamydia: Systematic Review to Update the U.S. Preventive Services Task Force Recommendations Evidence Synthesis Number 115 Screening for Gonorrhea and Chlamydia: Systematic Review to Update the U.S. Preventive Services Task Force Recommendations Prepared for: Agency for Healthcare Research and

More information

THE UNITED REPUBLIC OF TANZANIA MINISTRY OF HEALTH AND SOCIAL WELFARE

THE UNITED REPUBLIC OF TANZANIA MINISTRY OF HEALTH AND SOCIAL WELFARE THE UNITED REPUBLIC OF TANZANIA Treat for Lymphogranuloma venereum MINISTRY OF HEALTH AND SOCIAL WELFARE Appoint to return after Patient complains of Use Discharge from Continue to 2nd Refer to surgeon

More information

Allegheny County Health Department STD/HIV Program

Allegheny County Health Department STD/HIV Program Allegheny County Health Department STD/HIV Program 213 Annual STD Report UPMC 3441 Forbes Avenue Pittsburgh, PA 15213 Tel (412) 578-881 Fax (412)-578-83 www.county.allegheny.pa.us/achd/std info@achd.net

More information

2014 CDC Treatment Guidelines for STDs What s New, What s Important, What s Essential. STD Treatment Guidelines. How are the guidelines prepared?

2014 CDC Treatment Guidelines for STDs What s New, What s Important, What s Essential. STD Treatment Guidelines. How are the guidelines prepared? 2014 CDC Treatment Guidelines for STDs What s New, What s Important, What s Essential Bradley Stoner, MD, PhD Associate Professor, Washington University School of Medicine Medical Director, St. Louis STD/HIV

More information

Chlamydia. Looking after your sexual health

Chlamydia. Looking after your sexual health Chlamydia Looking after your sexual health 2 Chlamydia Chlamydia is one of the most common sexually transmitted infections (STIs). It is very easy to treat and cure. Up to one in 10 sexually active young

More information

STD Testing NORTHWEST AIDS EDUCATION AND TRAINING CENTER. Shireesha Dhanireddy, MD Assistant Professor University of Washington

STD Testing NORTHWEST AIDS EDUCATION AND TRAINING CENTER. Shireesha Dhanireddy, MD Assistant Professor University of Washington NORTHWEST AIDS EDUCATION AND TRAINING CENTER STD Testing Shireesha Dhanireddy, MD Assistant Professor University of Washington Presentation prepared by: Presenter Last Updated: STD s and HIV Overview Patients

More information

Background: U.S. Estimates. Edward W. Hook, III, M.D. The Medical Value of Laboratory Testing for STI Management

Background: U.S. Estimates. Edward W. Hook, III, M.D. The Medical Value of Laboratory Testing for STI Management Edward W. Hook, III, M.D. The Medical Value of Laboratory Edward W. Hook III M.D. Departments of Medicine. Microbiology and Epidemiology University of Alabama at Birmingham Grant/Research Support: Consultant:

More information

Gonorrhea and Chlamydia version 5 1 13

Gonorrhea and Chlamydia version 5 1 13 2011-Fig 16. SR Gonorrhea and Chlamydia version 5 1 13 Khalil G. Ghanem, MD, PhD kghanem@jhmi.edu GONORRHEA Gonorrhea Rates, United States, 1941 2011 1 2011-Fig 17. SR 2011-Fig 19. SR 2011-Fig 21. SR Gonorrhea

More information

Patient Information Sheet

Patient Information Sheet Healthcare Worker exposure to a patient s blood What is a healthcare worker exposure? Patient Information Sheet Occasionally, health care workers come into contact with the blood or body fluids of their

More information

Gonorrhoea. Looking after your sexual health

Gonorrhoea. Looking after your sexual health Gonorrhoea Looking after your sexual health 2 Gonorrhoea Gonorrhoea is a bacterial sexually transmitted infection (STI). It can be painful and can cause serious health problems such as infertility in both

More information

Chlamydia trachomatis genital infection is the

Chlamydia trachomatis genital infection is the CME Activity Inside and Online CHLAMYDIA TESTING AND TREATMENT Take a sexual history of all patients, including adolescents anyone who is sexually active is at risk for chlamydia infection. Screen sexually

More information

Alberta Health. Notifiable Sexually Transmitted Infections & Human Immunodeficiency Virus. 2013 Annual Report. Surveillance and Assessment Branch

Alberta Health. Notifiable Sexually Transmitted Infections & Human Immunodeficiency Virus. 2013 Annual Report. Surveillance and Assessment Branch Alberta Health Notifiable Sexually Transmitted Infections & Human Immunodeficiency Virus 213 Annual Report Surveillance and Assessment Branch February 215 Suggestion Citation: Alberta Health, Surveillance

More information

HIV/AIDS Tool Kit. B. HIV/AIDS Questionnaire for Health Care Providers and Staff

HIV/AIDS Tool Kit. B. HIV/AIDS Questionnaire for Health Care Providers and Staff 8 HIV/AIDS Tool Kit B. HIV/AIDS Questionnaire for Health Care Providers and Staff FOR STAFF USE ONLY: SURVEY ID # HIV/AIDS KAP Questionnaire for Health Care Providers and Staff Introduction The goal of

More information

Leader's Resource. Note: Both men and women can have an STD without physical symptoms.

Leader's Resource. Note: Both men and women can have an STD without physical symptoms. Leader's Resource Information on Sexually Transmitted Diseases (STDs) Signs and Symptoms of STDs Note: Both men and women can have an STD without physical symptoms. Any of the following can indicate to

More information

HIV/AIDS: General Information & Testing in the Emergency Department

HIV/AIDS: General Information & Testing in the Emergency Department What Is HIV? HIV/AIDS: General Information & Testing in the Emergency Department HIV is the common name for the Human Immunodeficiency Virus. HIV is a retrovirus. This means it can enter the body s own

More information

Clinical Scenarios CODING AND BILLING 101. Daryn Eikner, Family Planning Council Ann Finn, Ann Finn Consulting

Clinical Scenarios CODING AND BILLING 101. Daryn Eikner, Family Planning Council Ann Finn, Ann Finn Consulting Clinical Scenarios CODING AND BILLING 101 Daryn Eikner, Family Planning Council Ann Finn, Ann Finn Consulting 1 Always remember Follow coding guidelines If you didn t write it down, it didn t happen The

More information

Sexually Transmitted Infections: The old, the new, the borrowed, the blue

Sexually Transmitted Infections: The old, the new, the borrowed, the blue Sexually Transmitted Infections: The old, the new, the borrowed, the blue AHI 2015 Annual Meeting April 24, 2015 Fareeda Haamid, DO Assistant Professor of Clinical Pediatrics Disclosures and Disclaimers

More information

SYNDROMIC CASE MANAGEMENT OF RTIs Advantages, Limitations, Optimization

SYNDROMIC CASE MANAGEMENT OF RTIs Advantages, Limitations, Optimization WHO COLLABORATING CENTRE FOR RESEARCH IN HUMAN REPRODUCTION Hôpitaux Universitaires de Genève SYNDROMIC CASE MANAGEMENT OF RTIs Advantages, Limitations, Optimization Dr SALONEY NAZEER Department of Gynaecology

More information

Sexually Transmitted Infections: Keeping Your Practices Up-to-Date

Sexually Transmitted Infections: Keeping Your Practices Up-to-Date Sexually Transmitted Infections: Keeping Your Practices Up-to-Date SAHM 2016 Annual Meeting March 12, 2016 Washington, DC Fareeda Haamid, DO Assistant Professor of Pediatrics Cynthia Holland-Hall, MD,

More information

How do you know if you have an STI? YOU DON'T. The only way to find out is with a pathology test

How do you know if you have an STI? YOU DON'T. The only way to find out is with a pathology test How do you know if you have an STI? YOU DON'T The only way to find out is with a pathology test Sexually Transmitted Infections (STIs) are very common They are caused by infectious organisms passed on

More information

X-Plain Sexually Transmitted Diseases Reference Summary

X-Plain Sexually Transmitted Diseases Reference Summary X-Plain Sexually Transmitted Diseases Reference Summary Introduction Sexually transmitted diseases, or STDs, are some of the most common infectious diseases in the United States. There are more than 20

More information

Sexually Transmitted Infections

Sexually Transmitted Infections Introduction and General Considerations Date Reviewed: July, 2010 Section: 5-10 Page 1 of 13 Background Information The incidence of Sexually Transmitted Infections (STIs) in Saskatchewan has been increasing

More information

National Chlamydia Screening Programme September 2012 PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF AZITHROMYCIN FOR CHLAMYDIA TRACHOMATIS

National Chlamydia Screening Programme September 2012 PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF AZITHROMYCIN FOR CHLAMYDIA TRACHOMATIS PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF AZITHROMYCIN FOR CHLAMYDIA TRACHOMATIS Below is a template that can be used to produce a local patient group direction (PGD) for the administration of

More information

The special authority and Hospital Medicines List restriction was removed from 1 March 2016 (Pharmac). This is recommended first line treatment.

The special authority and Hospital Medicines List restriction was removed from 1 March 2016 (Pharmac). This is recommended first line treatment. Genital Herpes Summary of Guidelines Taken from: Guidelines for the Management of Genital Herpes in New Zealand 11th Edition - 2015 www.herpes.org.nz Genital Herpes Key Management Points Genital herpes

More information

Nurse Initiated STI Treatment Code

Nurse Initiated STI Treatment Code Nurse Initiated STI Treatment Code Public Health and Clinical Services Division June 2012 FORWARD The Nurse Initiated STI Treatment Code establishes the competencies which must be achieved and criteria

More information

Expedited Partner Therapy for Chlamydia Trachomatis and Neisseria Gonorrhoeae: Guidance for Health Care Professionals in Indiana

Expedited Partner Therapy for Chlamydia Trachomatis and Neisseria Gonorrhoeae: Guidance for Health Care Professionals in Indiana Indiana State Department of Health Introduction Expedited Partner Therapy for Chlamydia Trachomatis and Neisseria Gonorrhoeae: Guidance for Health Care Professionals in Indiana Indiana State Department

More information

Trichomonas vaginalis. Looking after your sexual health

Trichomonas vaginalis. Looking after your sexual health Trichomonas vaginalis Looking after your sexual health 2 3 Trichomonas vaginalis Trichomonas vaginalis is a sexually transmitted infection (STI). It is sometimes referred to as trichomonas or trichomoniasis,

More information

Men s Preventive Services: Proposed Guidelines

Men s Preventive Services: Proposed Guidelines www.menshealthlibrary.org Men s Health Network Veterans Health Council September 2011 updated January 2012 The additional preventive services for women, initiated by the passage of the Affordable Care

More information

Say AHHH! : STDs in Maine

Say AHHH! : STDs in Maine Say AHHH! : STDs in Maine Emer S. Smith, MPH Maine Center for Disease Control & Prevention HIV, STD, & Viral Hepatitis Program October 6, 2014 Review of STDs In Today s Talk... Epidemiology (Maine & U.S.)

More information

In Long Beach, services are available Tuesday & Thursday 9 a.m.-12 p.m. and 1-4 p.m. Call for information.

In Long Beach, services are available Tuesday & Thursday 9 a.m.-12 p.m. and 1-4 p.m. Call for information. In recognition of April being National STD Awareness Month, let s take some time to understand the impact of sexually transmitted diseases in Los Angeles. In Los Angeles County the two groups most impacted

More information

Frequently Asked Questions

Frequently Asked Questions PPFA HPV FAQ.qxd /11 2:15 PM Page 1 Frequently Asked Questions PPFA HPV FAQ.qxd /11 2:15 PM Page 2 PPFA HPV FAQ.qxd /11 2:15 PM Page 3 General Questions About HPV PPFA HPV FAQ.qxd /11 2:15 PM Page 4 PPFA

More information

Acute pelvic inflammatory disease: tests and treatment

Acute pelvic inflammatory disease: tests and treatment Acute pelvic inflammatory disease: tests and treatment Information for you Information for you Published August 2010 Published in August 2010 (next review date: 2014) Acute What is pelvic inflammatory

More information

Laboratory confirmation requires isolation of Bordetella pertussis or detection of B. pertussis nucleic acid, preferably from a nasopharyngeal swab.

Laboratory confirmation requires isolation of Bordetella pertussis or detection of B. pertussis nucleic acid, preferably from a nasopharyngeal swab. Pertussis Epidemiology in New Zealand New Zealand has continued to experience outbreaks of pertussis in recent decades. This is in part due to historically low immunisation rates and in part because immunity

More information

Forsyth County, North Carolina 2014 HIV/STD Surveillance Report

Forsyth County, North Carolina 2014 HIV/STD Surveillance Report Forsyth County, North Carolina 2014 HIV/STD Surveillance Report Forsyth County Department of Public Health Division of Epidemiology and Surveillance 799 N. Highland Avenue Winston-Salem, NC 27102-0686

More information

Sexually Transmitted. Diseases. Damon Wang. Diseases

Sexually Transmitted. Diseases. Damon Wang. Diseases Chlamydia by oral, anal, and vaginal sex, or by vaginal childbirth Symptoms in women include vaginal bleeding or discharge, abdominal pain, fever, painful urination, and urgent urination; 50-70% of infected

More information

Chlamydia Challenge. CONTENTS 2010 CDC STD Treatment Guidelines SPRING 11. Texas Oklahoma Louisiana Arkansas New Mexico

Chlamydia Challenge. CONTENTS 2010 CDC STD Treatment Guidelines SPRING 11. Texas Oklahoma Louisiana Arkansas New Mexico Chlamydia Challenge SPRING 11 Region VI Infertility Prevention Advisory Committee (RIPAC) Arkansas, Louisiana, New Mexico, Oklahoma and Texas CONTENTS 2010 CDC STD Treatment Guidelines REGIONAL UPDATES:

More information

New Guidelines for Detection and Treatment of Sexually Transmitted Infections

New Guidelines for Detection and Treatment of Sexually Transmitted Infections UCSF Primary Care Medicine: Principles and Practice October 23, New Guidelines for Detection and Treatment of Sexually Transmitted Infections There are no relevant financial relationships with any commercial

More information

Preventing Cervical Cancer with Gardasil Jana Ogden RN, MSN, MBA-HCA, IHCC Nursing Faculty. Upon Completion of the Lesson the student will be able to:

Preventing Cervical Cancer with Gardasil Jana Ogden RN, MSN, MBA-HCA, IHCC Nursing Faculty. Upon Completion of the Lesson the student will be able to: Preventing Cervical Cancer with Gardasil Jana Ogden RN, MSN, MBA-HCA, IHCC Nursing Faculty Upon Completion of the Lesson the student will be able to: Review statistics related to cervical cancer and HPV

More information

Gonoccocal Resistance to Antimicrobials Surveillance Programme (GRASP) Action Plan for England and Wales: Informing the Public Health Response

Gonoccocal Resistance to Antimicrobials Surveillance Programme (GRASP) Action Plan for England and Wales: Informing the Public Health Response // The main title of the report Gonoccocal Resistance to Antimicrobials Surveillance Programme (GRASP) Action Plan for England and Wales: Informing the Public Health Response February 2013 Contents Foreword

More information

Return of the Clap. Iide Gonorrhea colony, as seen under a microscope Image: Juergen Berger/Photo Researchers, Inc.

Return of the Clap. Iide Gonorrhea colony, as seen under a microscope Image: Juergen Berger/Photo Researchers, Inc. Return of the Clap Iide Gonorrhea colony, as seen under a microscope Image: Juergen Berger/Photo Researchers, Inc. Gonorrhea, once a minor illness, is developing resistance to the last category of drugs

More information

FDA-Approved Patient Information

FDA-Approved Patient Information FDA-Approved Patient Information PATIENT INFORMATION Mirena (Mur-ā-nah) (levonorgestrel-releasing intrauterine system) Mirena does not protect against HIV infection (AIDS) and other sexually transmitted

More information

Safe & Unsafe. abortion

Safe & Unsafe. abortion Safe & Unsafe Facts About abortion WHAT IS THE DIFFERENCE BETWEEN UNSAFE AND SAFE ABORTION? What is unsafe abortion? Unsafe abortion is a procedure for terminating an unplanned pregnancy either by a person

More information

Urinary Tract Infections in Adults

Urinary Tract Infections in Adults Urinary Tract Infections in Adults Urinary tract infections (UTIs) are responsible for more than seven million visits to physicians' offices per year and about 5 five percent of all visits to primary care

More information

McKinley Health Center

McKinley Health Center McKinley Health Center STDs (Sexually Transmitted Diseases) What are STDs? Sexually Transmitted Diseases (STDs) are diseases passed from one person to another during sexual activity. STDs can be serious,

More information

Yes, I know I have genital herpes:

Yes, I know I have genital herpes: Counseling Messages for Herpes Simplex Type II (HSV-II) Genital herpes Always take the time to attend to the participant s feelings and emotional state; for some people, this is the most devastating news

More information

CONTROL OF NEISSERIA GONORRHOEAE INFECTION IN THE UNITED STATES

CONTROL OF NEISSERIA GONORRHOEAE INFECTION IN THE UNITED STATES CONTROL OF NEISSERIA GONORRHOEAE INFECTION IN THE UNITED STATES REPORT OF AN EXTERNAL CONSULTANTS MEETING CONVENED BY THE DIVISION OF STD PREVENTION, NATIONAL CENTER FOR HIV, STD, AND TB PREVENTION, CENTERS

More information

Antimicrobial Resistance & Infections. Clinical Perspectives

Antimicrobial Resistance & Infections. Clinical Perspectives Antimicrobial Resistance & Sexually Transmitted Infections Clinical Perspectives Outline Neisseria gonorrhoeae Global threat of untreatable gonorrhoea Mycoplasma genitalium Rapid loss of treatment options

More information

Teens, Sexually Transmitted Diseases & HIV / AIDS AVERT

Teens, Sexually Transmitted Diseases & HIV / AIDS AVERT Teens, Sexually Transmitted Diseases & HIV / AIDS By AVERT What are STDs? STD stands for Sexually Transmitted Disease (sometimes called Sexually Transmitted Infection). This is an infection which can be

More information

Pharmacist Prescribing for UTI: The Burning Question of Self Diagnosis

Pharmacist Prescribing for UTI: The Burning Question of Self Diagnosis for UTI: The Burning Question of Self Diagnosis Overview Review Pharmacist prescribing in Saskatchewan Discuss current management / diagnosis of UTI Appraise the literature for safe and accurate diagnosis

More information

Preface. TTY: (888) 232-6348 or cdcinfo@cdc.gov. Hepatitis C Counseling and Testing, contact: 800-CDC-INFO (800-232-4636)

Preface. TTY: (888) 232-6348 or cdcinfo@cdc.gov. Hepatitis C Counseling and Testing, contact: 800-CDC-INFO (800-232-4636) Preface The purpose of this CDC Hepatitis C Counseling and Testing manual is to provide guidance for hepatitis C counseling and testing of individuals born during 1945 1965. The guide was used in draft

More information

Birth Control Options

Birth Control Options 1 of 5 6/2/2014 9:46 AM Return to Web version Birth Control Options What is contraception? Contraception means preventing pregnancy, also called birth control. Most people know about options such as birth

More information

Teen Talk s Sexual Jeopardy Game

Teen Talk s Sexual Jeopardy Game Teen Talk s Sexual Jeopardy Game Goal: To have fun while educating, linking youth to local resources and reinforcing information learned about sexual health topics; including STIs, HIV, birth control,

More information

NOTICE OF PUBLIC HEARING REGARDING PROPOSED CHANGES IN HEALTH CARE SERVICES PROVIDED BY FRESNO COUNTY

NOTICE OF PUBLIC HEARING REGARDING PROPOSED CHANGES IN HEALTH CARE SERVICES PROVIDED BY FRESNO COUNTY NOTICE IS HEREBY GIVEN that a public hearing will commence on Tuesday, September 23, 2008, at 9:00 a.m. (subject to continuance on that date of the hearing) at the Fresno County Board of Supervisors Chambers,

More information